PhD in Biomedical Sciences and Biotechnology

 

Home –  PhD students –  Faculty –  Seminars

 

  1. Tumedei MM, Silvestrini R, Ravaioli S, Massa I, Maltoni R, Rocca A, Folli S, Buggi F, Curcio A, Serra L, Puccetti M, Amadori D, Bravaccini S. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast. Int J Biol Markers. 2015 Nov 11;30(4): e425-8. doi: 10.5301/jbm.5000163.PMID: 26165687
  2. Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, Lazzari E, Crews LA, Jamieson CH, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820. PMID: 27463014
  3. Ravaioli S, Tumedei MM, Amadori A, Puccetti M, Chiadini E, Bravaccini S. Role of Telomerase in Cervical Lesions as Prognostic Marker: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization. J Low Genit Tract Dis. 2017 Jan; 21(1):42-46. doi: 10.1097/LGT.0000000000000261. PMID:27611439
  4. Ravaioli S, Bravaccini S, Tumedei MM, Pironi F, Candoli P, Puccetti M. Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology. Oncotarget. 2017 Feb 14;8(7):11199-11205. doi: 10.18632/oncotarget.13204.  PMID: 27833073
  5. Casadio V, Salvi S, Martignano F, Gunelli R, Ravaioli S, Calistri D. Cell-Free DNA Integrity Analysis in Urine Samples. J Vis Exp. 2017 Jan 5;(119). doi: 10.3791/55049. PMID:28117781
  6. Maltoni R, Casadio V*, Ravaioli S*, Foca F, Tumedei MM, Salvi S, Martignano F, Calistri D, Rocca A, Schirone A, Amadori D, Bravaccini S. Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.Oncotarget. 2017 Mar 7;8(10):16642-16649. doi:10.18632/oncotarget.15120. PMID: 28186965 *equally contributed
  7. Ravaioli S, Puccetti M, Tumedei MM, Silvestrini R, Bedei L, Bravaccini S. Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? Appl Immunohistochem Mol Morphol. 2017 Sep 29. doi: 10.1097/PAI.0000000000000582. PMID: 28968271
  8. Ravaioli S, Tumedei MM, Foca F, Maltoni R, Rocca A, Massa I, Pietri E, Bravaccini S. Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy. Int J Exp Pathol. 2017 Oct;98(5):289-295. doi: 10.1111/iep.12253. Epub 2017 Nov 28.PMID:29193395
  9. Bronte G, Ravaioli S, Bravaccini S. What to look for in cell-free DNA from breast cancer patients. Breast Cancer Res Treat. 2018 Feb 26. doi: 10.1007/s10549-018-4728-8. PMID:29480448
  10. Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018 Mar 9;8(1):4254. doi: 10.1038/s41598-018-22594-1.PMID:29523813
  11. Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, Andreis D, Maltoni R, Sarti S, Cecconetto L, Fedeli A, Pietri E, De Simone V, Asioli S, Amadori D, Bravaccini S. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? BMC Cancer. 2018 Mar 27;18(1):348. doi: 10.1186/s12885-018-4239-3. PMID:29587674
  12. Bravaccini S, Ravaioli S, Amadori D, Scarpi E, Puccetti M, Rocca A, Tumedei MM, Masalu N, Kahima J, Pangan A, Faustine L, Farolfi A, Maltoni R, Bonafè M, Serra P, Bronte G. Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018. PMID:29651273
  13. Puccetti M*, Ravaioli S*, Tumedei MM, Bucchi E, Malmesi M, Medri L, Bravaccini S. Are FNAB-derived cell blocks a useful surrogate for tissue samples in breast cancer? Histopathology. 2018 Jun 26. doi: 10.1111/his.13694. PMID: 29944734 *equally contributed
  14. Bronte G, Bravaccini S, Ravaioli S, Puccetti M, Scarpi E, Andreis D, Tumedei MM, Sarti S, Cecconetto L, Pietri E, De Simone V, Maltoni R, Bonafè M, Amadori D, Rocca A. Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? Transl Oncol. 2018 Aug;11(4):950-956. doi: 10.1016/j.tranon.2018.05.006. Epub 2018 Jun 18.
  15. Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A. Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.Oncologist. 2018 Dec 27. pii: theoncologist.2018-0243.
  16. D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaioli S, Tumedei MM, Incarbone M, Cappuzzo F. Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. Oncotarget. 2019 Jan 15;10(5):561-572.
  17. Ravaioli S. Cell-Free DNA Integrity: Applications. Methods Mol Biol. 2019;1909:77-83.
  18. Bronte G, Rocca A, Ravaioli S*, Scarpi E, Bonafè M, Puccetti M, Maltoni R, Andreis D, Martinelli G, Bravaccini S. Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? J Oncol. 2019 Apr 14;2019:1393505. *corresponding author
  19. Bravaccini S, Bucchi L, Puccetti M, Ravaioli S, Tumedei MM, Serra P, Masini C, Kahima J, Masalu N, Amadori D. Explaining the aggressiveness of breast cancer in sub-Saharan African patients. J Clin Pathol. 2019 Oct;72(10):723-724. doi: 10.1136/jclinpath-2019-206071. Epub 2019 Aug 13.